Bristol, Sept. 12 -- Myers Squibb Company has announced that its Board of Directors has elected three new independent Directors: Michael Bonney, Dr. Julia A. Haller and Phyllis Yale will join the Board effective at the closing of the transaction with Celgene Corporation. In connection with these elections, the size of the Board will increase at the time of the transaction close. Mr. Bonney and Dr. Haller currently serve on Celgene's Board of Directors.

"I am extremely pleased to add Michael, Julia and Phyllis to Bristol-Myers Squibb's Board. These three leaders bring skill sets and experience that complement our current Board members," said Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol-Myers Squibb. "With these ...